Opportunities
Search

Buyer: ČEZ, a. s. | Notice type: cn-standard | Procedure: neg-w-call | Contract: services | Deadline: 2026-10-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Nordost - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: Gemeente Rotterdam | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: Gemeente Rotterdam | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the Military Health System (MHS).Distinctive Features:• Applications must include preliminary data to support feasibility of the study.• Projects must have strong potential to result in a near-term impact in cancer.• The funding mechanism allows clinical trials.• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, both applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to Service Members, Veterans, other military beneficiaries and the American public.Distinctive Features: The proposed project should demonstrate creative thinking and innovation.• Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not appropriate for this award.• Inclusion of preliminary data is not required; however, the project must be based on strong scientific rationale.• New for FY26: Early Career Investigator Option: The Early Career Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.Distinctive Features:• Applications to this award mechanism must include a clinical trial.• Projects can range from phase 0 to phase III.• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.• Applications are required to include patient advocates.• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Objective:The objective of this call is to modernise maritime transport infrastructure on the TEN-T network and reducing the environmental impact of transport through efficient short sea shipping links and greening of inland shipping.Scope:Only works projects related to:Projects supporting the deployment of Onshore-power supply and charging infrastructure in TEN-T maritime and inland ports in accordance with Regulation 2023/1804 [1].The fitting or retrofitting of the energy systems of inland waterway vessels and short sea shipping vessels (including ferries) [2], with electric, hybrid, H2, ammonia, methanol and biomethane technologies, substitute sources of energy [3] and the installation of wind assisted propulsion systems (WAPS). For projects supporting the deployment of Onshore-power supply and charging infrastructure in TEN-T maritime and inland ports:Projects may include Onshore-pow...

Objective:The objective of this call is to develop rail transport infrastructure projects on the TEN-T core[1] network. Scope:Works and / or studies related to: Construction/upgrading of cross-border and missing links; Interconnections between rail and other modes of transport, namely inland waterway and maritime transport (including port hinterland connections) and projects aimed at the integration of the high-speed rail and air networks to make the feeder network for long-haul flights more sustainable. Priority will be given to projects fostering the development of high-speed rail in line with the Commission communication on high-speed rail [2].Support will not be given to railway stations, except for railway infrastructure components. If the project includes such components, they shall be presented as a separate work package. Support will not be given to track side ERTMS deployment, e...